Persistence of antibodies acquired by natural hepatitis E virus infection and effects of vaccination

Su, Yingying; Huang, Shou-Jie; Guo, Meng; Zhao, Jinghua; Yu, Hai; He, Wenzheng; Jiang, Han-Min; Wang, Y.-J.; Zhang, X.-F.; Cai, Jia-Ping; Yang, Chang‐Lin; Wang, Z.-Z.; Zhu, Fengcai; Wu, Ting; Zhang, J.; Xia, Ningshao

doi:10.1016/j.cmi.2016.10.029

Cited by 22 publications

(14 citation statements)

References 10 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…84 It is predicted that HEV239 vaccine-induced IgG is detectable to provide protection for nearly a lifetime. 85,86 Interestingly, the study area is endemic for HEV genotype 4, suggesting that the vaccine-induced antibodies conferred cross-genotype protection, consistent with the findings from the previous animal studies. 46,87 This vaccine has now been approved by the China Food and Drug Administration.…”

Section: T Cell Exhaustion In Chronic Hepatitis Esupporting

confidence: 88%

“…Follow‐up studies have demonstrated that this high efficacy is maintained to effectively protect the population against HEV infection . It is predicted that HEV239 vaccine‐induced IgG is detectable to provide protection for nearly a lifetime . Interestingly, the study area is endemic for HEV genotype 4, suggesting that the vaccine‐induced antibodies conferred cross‐genotype protection, consistent with the findings from the previous animal studies .…”

Section: Development Of Hev Vaccinessupporting

confidence: 86%

See 1 more Smart Citation

Immunity against hepatitis E virus infection: Implications for therapy and vaccine development

Hakim

Ikram

Zhou

et al. 2017

Reviews in Medical Virology

View full text Add to dashboard Cite

Hepatitis E virus (HEV) is the leading cause of acute viral hepatitis worldwide and an emerging cause of chronic infection in immunocompromised patients. As with viral infections in general, immune responses are critical to determine the outcome of HEV infection. Accumulating studies in cell culture, animal models and patients have improved our understanding of HEV immunopathogenesis and informed the development of new antiviral therapies and effective vaccines. In this review, we discuss the recent progress on innate and adaptive immunity in HEV infection, and the implications for the devolopment of effective vaccines and immune-based therapies.

show abstract

Section: T Cell Exhaustion In Chronic Hepatitis Esupporting

confidence: 88%

Section: Development Of Hev Vaccinessupporting

confidence: 86%

Immunity against hepatitis E virus infection: Implications for therapy and vaccine development

Hakim

Ikram

Zhou

et al. 2017

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…Modeling suggests that it could provide protection for up to 30 years after vaccination (Su et al 2017). Strategies for using this vaccine outside China have not been defined yet for either human or pig populations.…”

Section: Vaccinesmentioning

confidence: 99%

Transmission and Epidemiology of Hepatitis E Virus Genotype 3 and 4 Infections

Dalton

Izopet

2018

Cold Spring Harb Perspect Med

View full text Add to dashboard Cite

Following the introduction of robust serological and molecular tools, our understanding of the epidemiology of zoonotic hepatitis E virus (HEV) has improved considerably in recent years. Current thinking suggests that consumption of pork meat products is the key route of infection in humans, but it is certainly not the only one. Other routes of infection include environmental spread, contaminated water, and via the human blood supply. The epidemiology of HEV genotype (gt)3 and gt4 is complex, as there are several sources and routes of infection, and it is likely that these vary between and within countries and over time.

show abstract

“…The immunogenicity and safety of hepatitis E vaccine has been documented in HBV carriers [ 34 ], but no similar studies are available among CHB, cirrhosis and HCC patients. Given the fact that most CHB patients develop from HBV carriers and the long-lasting anti-HEV IgG induced by hepatitis E vaccine has been documented [ 35 ], hepatitis E vaccine is recommended to HBV carriers to prevent HBV-HEV superinfection, especially in HEV hyperendemic areas.…”

Section: Discussionmentioning

confidence: 99%

Comparison of hepatitis E virus seroprevalence between HBsAg-positive population and healthy controls in Shandong province, China

Zhang

Jiang²,

et al. 2018

BMC Infect Dis

View full text Add to dashboard Cite

BackgroundPersons with chronic hepatitis B (CHB) infection were reported to suffer severe disease after hepatitis E virus (HEV) superinfection, but the studies regarding HEV seroprevalence in this population were limited. A recent study in Vietnam found higher HEV seroprevalence among CHB patients compared with healthy controls.MethodsA community-based case-control study was conducted in two counties of Shandong province, China, where hepatitis E incidence was at the highest (Rushan) and lowest (Zhangqiu) in the province based on data from routine public health surveillance. Four townships were selected randomly from each county and all residents in these townships were tested for hepatitis B surface antigen (HBsAg). Those tested positive for HBsAg (CHB group) and the 1:1 age and sex-matched HBsAg-negative residents (control group) were included. Anti-HEV IgM and IgG were tested and positive rates of IgG and IgM were compared between the CHB group and the control group.ResultsIn total, 2048 CHB participants and 2054 controls were included in the study. In the CHB group, HEV IgG seroprevalence was 9.16% (95% CI: 7.47–11.09) in Zhangqiue and 38.06% (95% CI: 35.07–41.19) in Rushan (P < 0.001); the corresponding rates of IgM were 0.1% (95% CI: 0.002–0.54) and 1.57% (95% CI: 0.90–2.53), respectively (P < 0.001). HEV IgG seroprevalence was similar between CHB group and the control group in both counties (P = 0.21, P = 0.47, respectively) and the same results were found for the positive rate of IgM (P = 0.103, P = 0.262, respectively). Multivariable analysis showed the status of HBsAg was not independently associated with the status of anti-HEV IgG in either Zhangqiu or Rushan [P = 0.187, OR = 1.23(95% CI: 0.90, 1.68); P = 0.609, OR = 1.05 (95% CI: 0.87, 1.26)].ConclusionsThe seroprevalence of HEV varies greatly in different geographic areas, but the seroprevalence is similar between populations with and without CHB. CHB patients residing in high HEV endemic areas might be at higher risk for HBV-HEV superinfection.

show abstract

Persistence of antibodies acquired by natural hepatitis E virus infection and effects of vaccination

Abstract: Whereas naturally acquired anti-HEV IgG levels decrease steadily, HEV vaccination induces long-lasting, high-level anti-HEV IgG concentrations.

Cited by 22 publications

References 10 publications

Immunity against hepatitis E virus infection: Implications for therapy and vaccine development

Immunity against hepatitis E virus infection: Implications for therapy and vaccine development

Transmission and Epidemiology of Hepatitis E Virus Genotype 3 and 4 Infections

Comparison of hepatitis E virus seroprevalence between HBsAg-positive population and healthy controls in Shandong province, China

Contact Info

Product

Resources

About